# A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

> **NCT06349980** · PHASE2 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 117 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** HLX53 (1000mg)
- **DRUG:** HLX53 (2000mg)
- **DRUG:** HLX10
- **DRUG:** HLX04
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06349980
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-05
- **Primary completion:** 2027-02-10
- **Final completion:** 2027-02-10
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06349980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06349980, "A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06349980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*